Understand the source comparison
Appetite Suppression Peptides 2026 Update: Molecule Comparison
Semaglutide GLP-1 14.9% ~7 days Approved (Wegovy, Ozempic) First-generation benchmark. Proven efficacy but receptor desensitization limits long-term sustainability without dose increases Tirzepatide GLP-1 + GIP 20.9% ~5 days Approved (Mounjaro, Zepbound) Dual-
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Semaglutide
- GLP-1
- 14.9%
- ~7 days
- Approved (Wegovy, Ozempic)
- First-generation benchmark. Proven efficacy but receptor desensitization limits long-term sustainability without dose increases
- Tirzepatide
- GLP-1 + GIP
- 20.9%
- ~5 days
- Approved (Mounjaro, Zepbound)
- Dual-receptor mechanism reduces plateau risk. Currently the gold standard for weight loss magnitude
- Survodutide
- GLP-1 + Glucagon
- 18.6%
- ~6 days
- Phase 3 (FDA fast-track)
- Glucagon component adds metabolic rate elevation. Expected approval Q3 2026 based on SYNCHRONIZE-1 data
- Mazdutide
- 16.2% (32 weeks)
- Phase 2b
- Superior lean mass preservation (22% vs 31–35% typical). Strongest metabolic health profile among current candidates
- Retatrutide
- GLP-1 + GIP + Glucagon
- 24.2% (48 weeks)
- Phase 2 (Eli Lilly)
- Triple-receptor agonist. Highest weight loss observed in trials but GI side effects remain dose-limiting for some patients
- Survodutide and mazdutide represent the immediate next wave. Commercially viable within 12–18 months. Retatrutide's triple-agonist mechanism is mechanistically elegant but faces higher regulatory scrutiny due to its novelty.